Physician profile
Christopher Reyes
NPI 1407828940
$7,033.06
in general payments reported to CMS, 2019-2025
37 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $232 · 2021: $1,235 · 2022: $897 · 2023: $1,086 · 2024: $1,378 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,984.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,586.16 | 2021-2025 | |
| Lilly USA, LLC | $1,120.40 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $781.92 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $700.06 | 2020-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $462.89 | 2019-2025 | |
| Pfizer INC. | $416.37 | 2019-2025 | |
| Mylan Specialty L.P. | $223.71 | 2019-2023 | Yupelri |
| Amgen INC. | $207.84 | 2022-2024 | Evenity, Prolia |
| Sumitomo Pharma America, INC. | $207.71 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $131.87 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $127.84 | 2021-2025 | |
| Amarin Pharma, INC. | $99.49 | 2020-2021 | |
| Glaxosmithkline, LLC. | $98.21 | 2019-2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $95.55 | 2020-2024 | Capvaxive, Gardasil 9, Gardasil |
| Eisai INC. | $90.73 | 2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Reyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.